Thursday, 6 September 2012

Eli Lilly’s solanezumab faces grim prospects of attaining conditional FDA approval in mild Alzheimer’s

Check out this link to the Financial Times

http://www.ft.com/cms/s/2/cbc228be-f6d3-11e1-827f-00144feabdc0.html#axzz25j8NA1Vp
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Mild Parkinsonian Signs in a Community Population

One question that many of the PREDICT-PD participants ask me is “I am slower than I used to be, does it mean that I am getting Parkinson’...